NeuroPace (NASDAQ:NPCE) Stock Rating Cut to “Equal Weight” at Wells Fargo & Company

NeuroPace (NASDAQ:NPCE) was downgraded by Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a report issued on Friday, Briefing.com reports. They presently have a $9.00 target price on the stock. Wells Fargo & Company‘s price target would indicate a potential downside of 25.12% from the stock’s current price.

A number of other equities research analysts have also recently commented on the company. Raymond James Financial set a $21.00 price objective on NeuroPace in a research note on Tuesday, September 15th. Guggenheim reaffirmed a “neutral” rating on shares of NeuroPace in a research report on Wednesday, July 29th. JPMorgan Chase & Co. lowered NeuroPace from an “overweight” rating to a “neutral” rating and set a $9.00 target price on the stock. in a research report on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of NeuroPace in a report on Tuesday, September 15th. Finally, Weiss Ratings downgraded shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, NeuroPace currently has a consensus rating of “Hold” and a consensus price target of $15.50.

NeuroPace Stock Performance

Shares of NPCE opened at $12.02 on Friday. NeuroPace has a one year low of $11.90 and a one year high of $19.60. The company has a market cap of $412.53 million, a PE ratio of -21.09 and a beta of 1.98. The stock has a 50-day moving average of $13.35 and a 200-day moving average of $14.79. The company has a debt-to-equity ratio of 4.97, a current ratio of 4.94 and a quick ratio of 3.91.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. The business had revenue of $22.83 million for the quarter, compared to the consensus estimate of $22.61 million. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%. On average, equities research analysts predict that NeuroPace will post -0.67 EPS for the current fiscal year.

Institutional Trading of NeuroPace

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NPCE. Legal & General Group Plc purchased a new stake in shares of NeuroPace in the second quarter worth approximately $41,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of NeuroPace in the second quarter valued at approximately $157,000. Diversified Trust Co purchased a new position in shares of NeuroPace during the third quarter valued at approximately $153,000. Bank of America Corp DE purchased a new position in shares of NeuroPace during the second quarter valued at approximately $322,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of NeuroPace during the second quarter valued at approximately $351,000. 78.83% of the stock is owned by institutional investors.

NeuroPace News Summary

These are some of the NPCE news items that stood out recently:

• Positive Sentiment: NeuroPace reported a quarterly loss of $0.03 per share, narrower than the $0.11 loss analysts expected and the $0.11 loss a year earlier. Zacks article
• Negative Sentiment: Revenue was $23.1 million, below analysts’ $27.12 million expectation. RNS System revenue was $22.9 million, up just 1.4% year over year, pointing to limited growth. NeuroPace earnings release
• Negative Sentiment: The company lowered its 2026 revenue outlook to $91 million–$92 million, well below the roughly $100.4 million analyst consensus. The guidance reduction, alongside the quarterly revenue miss, is the clearest near-term negative catalyst for NPCE shares. Coverage of NeuroPace’s reduced guidance

About NeuroPace

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.